Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 99M | 99M | 96M | 91M | 84M |
| Gross Profit | 7M | 94M | 90M | 86M | 80M |
| Operating Income | 39M | 37M | 31M | 31M | 29M |
| EBITDA | 81M | 70M | 65M | 58M | 145M |
| Net Income | 18M | 19M | 15M | 21M | 109M |
| EPS (Diluted) | — | — | — | — | — |
Real Estate
Live Price
Offline$37.86
-2.35% today
1Y Change
-1.80%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Universal Health Realty Income Trust (UHT) is a Real Estate stock with a market cap of $560.00M and listed on NYSE. The stock last traded around $37.86 and down 1.8% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +0.2%, EPS growth of -8.6%, a dividend yield of 7.3%. What stands out right now is revenue +0.2%, EPS -8.6%, free cash flow +4.6% with operating margin 36.2% and ROIC 146.1%. The dividend matters to the case here, with a current yield around 7.3%. Valuation already assumes a fairly strong business story at P/E 31.4 and price/sales 3.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines UHT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Real Estate peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
UHT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
UHT Max Drawdown
-15.96%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for UHT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$84.2M
-7.1% YoY
FY Net Income
$109.2M
+417.3% YoY
Free Cash Flow
$34.7M
+4.7% YoY
Revenue Growth
+0.2%
EPS Growth
-8.6%
Gross Margin
90.5%
Net Margin
12.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 99M | 99M | 96M | 91M | 84M |
| Gross Profit | 7M | 94M | 90M | 86M | 80M |
| Operating Income | 39M | 37M | 31M | 31M | 29M |
| EBITDA | 81M | 70M | 65M | 58M | 145M |
| Net Income | 18M | 19M | 15M | 21M | 109M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 7M | 7M | 8M | 8M | 23M |
| Total Assets | 565M | 581M | 596M | 608M | 598M |
| Total Liabilities | 413M | 401M | 395M | 378M | 363M |
| Shareholder Equity | 152M | 180M | 201M | 229M | 235M |
| Total Debt | 386M | 379M | 370M | 354M | 340M |
| Net Debt | 379M | 372M | 362M | 347M | 318M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
48M
+2.0% YoY
Capital Expenditures
13M
+4.6% YoY
Free Cash Flow
35M
+4.7% YoY
Key ratios
Gross Margin
90.5%
Operating Margin
36.2%
Net Margin
12.0%
ROE
11.4%
Debt / Equity
2.63x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.